Oxford BioMedica upbeat on Parkinson's programme despite analyst dissent
This article was originally published in Scrip
Executive Summary
Oxford BioMedica remains focused on furthering and partnering its Parkinson's disease treatment ProSavin after reporting interim data from a Phase I/II study looking at the safety, efficacy and dose evaluation of the product in patients at mid-stages of the condition.